Health Care & Life Sciences » Biotechnology | Celldex Therapeutics Inc.

Celldex Therapeutics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
302,983.00
201,043.00
289,889.00
189,176.00
139,127.00
Total Accounts Receivable
489.00
427.00
970.00
2,384.00
2,180.00
Other Current Assets
1,717.00
3,515.00
4,077.00
4,009.00
3,449.00
Total Current Assets
305,189.00
204,985.00
294,936.00
195,569.00
144,756.00
Net Property, Plant & Equipment
9,973.00
10,535.00
11,461.00
13,192.00
10,372.00
Intangible Assets
31,785.00
30,772.00
29,759.00
172,463.00
158,567.00
Other Assets
148.00
1,722.00
1,428.00
2,134.00
1,929.00
Total Assets
347,095.00
248,014.00
337,584.00
383,358.00
315,624.00
Accounts Payable
2,243.00
2,603.00
1,506.00
1,740.00
1,715.00
Other Current Liabilities
18,107.00
21,888.00
28,734.00
33,483.00
26,021.00
Total Current Liabilities
20,350.00
24,491.00
30,240.00
35,223.00
27,736.00
Other Liabilities
6,950.00
11,863.00
17,239.00
82,704.00
51,519.00
Total Liabilities
27,300.00
36,354.00
47,479.00
117,927.00
79,255.00
Common Equity (Total)
319,795.00
211,660.00
290,105.00
265,431.00
236,369.00
Total Shareholders' Equity
319,795.00
211,660.00
290,105.00
265,431.00
236,369.00
Total Equity
319,795.00
211,660.00
290,105.00
265,431.00
236,369.00
Liabilities & Shareholders' Equity
347,095.00
248,014.00
337,584.00
383,358.00
315,624.00

About Celldex Therapeutics

View Profile
Address
Perryville III Building
Hampton New Jersey 08827
United States
Employees -
Website http://www.celldex.com
Updated 09/14/2018
Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.